Log In
Print this Print this

Subcutaneous MOR103

  Manage Alerts
Collapse Summary General Information
Company MorphoSys AG
DescriptionSubcutaneous formulation of a human HuCal antibody against GM-CSF
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) receptor (CSF2RA) (GMR) (CD116)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard Indication Inflammation (unspecified)
Indication DetailsTreat chronic inflammatory diseases
Regulatory Designation
Partner GlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today